Discovery research and development history of the dopamine D 2 receptor partial agonists, aripiprazole and brexpiprazole-Reference-Cited by-同舟云学术

Discovery research and development history of the dopamine D 2 receptor partial agonists, aripiprazole and brexpiprazole

Published:2021-05-07 Issue:2 Volume:41 Page:134-143
ISSN:2574-173X
Container-title:Neuropsychopharmacology Reports
language:en
Short-container-title:Neuropsychopharmacol Rep

Author:

Kikuchi Tetsuro¹^ORCID,Maeda Kenji²,Suzuki Mikio³,Hirose Tsuyoshi¹,Futamura Takashi³,McQuade Robert D.⁴

Affiliation:

1. New Drug Research Division Pharmaceutical Business Division Otsuka Pharmaceutical Co., Ltd. Tokushima Japan

2. Department of Lead Discovery Research New Drug Research Division Pharmaceutical Business Division Otsuka Pharmaceutical Co., Ltd. Tokushima Japan

3. Department of CNS Research New Drug Research Division Pharmaceutical Business Division Otsuka Pharmaceutical Co., Ltd. Tokushima Japan

4. Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton NJ USA

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Clinical Psychology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/npr2.12180

Reference60 articles.

1. Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

2. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic

3. 7‐{4‐[4‐(2,3‐Dichlorophenyl)‐1‐piperazinyl]butyloxy}‐3,4‐dihydro‐2(1H)‐quinolinone (OPC‐14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity;Kikuchi T;J Pharmacol Exp Ther,1995

4. Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives

5. Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 2: Illustrating Their Mechanism of Action

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current treatments in schizophrenia;Prescriber;2024-09

2. Functional dizziness: from diagnostic criteria to clinical profiles and therapy. Expert consensus;Neurology, Neuropsychiatry, Psychosomatics;2024-08-19

3. Protecting Cerebral Blood Flow Autoregulation: A Frontier Study on Aripiprazole's Inhibition of the MAPK Signaling Pathway after Cerebral Ischemia;J BIOL REG HOMEOS AG;2024

4. Efficacy and tolerability of brexpiprazole – a new antipsychotic drug from the group of dopamine D2 receptor partial agonists;Psychiatria Polska;2024-04-09

5. Effects of Nostoc commune extract on the cerebral oxidative and neuroinflammatory status in a mice model of schizophrenia;Biochemistry and Biophysics Reports;2024-03